Designed for busy clinicians, this program provides
the key take-aways and practice-changing presentations from SABCS 2024.
Intended Audience
This official Best of SABCS program is directed to practicing oncologists (medical, surgical, radiation), community physicians, medical residents and fellows training in oncology, as well as other pertinent healthcare professionals involved in oncology medicine.
Learning Objectives
After completion of this program, attendees should be able to:
- APPLY evidence-based strategies for preventing, detecting, and diagnosing breast cancer in at-risk patients.
- CONDUCT biomarker and genetic testing in patients with breast cancer using evidence-based principles to identify actionable mutations and other tumor characteristics that influence treatment approaches.
- INCORPORATE new results from preclinical research and clinical trials in all aspects of breast cancer care presented during oral, poster and educational sessions at the annual San Antonio Breast Cancer Symposium into clinical practice.
- INTEGRATE new data from clinical trials of novel therapeutics in breast cancer into local treatment patterns to align current practices with evidence based approaches, overcome resistance mechanisms, and enhance patient outcomes.
- DESIGN treatment plans for patients with breast cancer using individualized treatment strategies based on breast cancer subtype, clinical characteristics, and patient preferences and goals to optimize therapy.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The UT Health Science Center San Antonio and Encore Medical Education. The UT Health Science Center San Antonio is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The UT Health Science Center San Antonio designates this live activity for a maximum of 5.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Duration:
Release: February 12, 2025
Expiration: November 1, 2025
Commercial Support
This program is supported by unrestricted educational grants from:
AstraZeneca, Daiichi Sankyo, Exact Sciences, Pfizer, Stemline/Menarini, and Puma Biotechnology
Agenda
Name | Speakers | Total Minutes | Credits | |
---|---|---|---|---|
Wednesday, February 12, 2025 | ||||
New Directions in Breast Cancer Prevention and Approaches to Risk Reduction | ![]() | Mili Arora, UC Davis Comprehensive Cancer Center | 29:03 | AMA PRA Category 1 Credits™ (.50 hour) |
Insights in Translational Research and Resistance Mechanisms | ![]() | Mark Pegram, Stanford University School of Medicine | 34:53 | AMA PRA Category 1 Credits™ (.50 hour) |
Advances in Approaches to Local-Regional Disease (Surgical and Radiation) | ![]() | Rita Mukhtar, UCSF | 30:41 | AMA PRA Category 1 Credits™ (.50 hour) |
Clinical Cases and Panel Discussion - Part 1 | ![]() | Hope Rugo, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center | 32:35 | AMA PRA Category 1 Credits™ (.50 hour) |
Updates in the Management of HR+ Early Stage Disease | ![]() | Helen Chew, UC Davis Comprehensive Cancer Center | 28:50 | AMA PRA Category 1 Credits™ (.50 hour) |
Updates in Management of HR+ Metastatic Disease | ![]() | Rebecca Shatsky, UC San Diego Moores Cancer Center | 29:51 | AMA PRA Category 1 Credits™ (.50 hour) |
Updates in the Management of Triple Negative Disease | ![]() | Jo Chien, UCSF Helen Diller Family Comprehensive Cancer Center | 28:47 | AMA PRA Category 1 Credits™ (.50 hour) |
Updates in Management of HER2+ Disease | ![]() | Melinda Telli, Stanford University School of Medicine | 33:23 | AMA PRA Category 1 Credits™ (.50 hour) |
Clinical Cases and Panel Discussion - Part 2 | ![]() | Hope Rugo, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center | 55:21 | AMA PRA Category 1 Credits™ (1.0 hour) |
Disclaimers
The opinions and comments expressed by faculty and other experts, whose input is included in this program, are their own. This enduring material is produced for educational purposes only. Please review complete prescribing information of specific drugs mentioned in this program including indications, contraindications, warnings, and adverse effects and dosage before administering to patients.
This material may not be published, broadcast, rewritten, or redistributed in any form without prior authorization from Encore Medical Education. Your use of this website constitutes acceptance of Encore Medical Education's Privacy Policy and Terms & Conditions.